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Abstract
Background: A definition of disease activity in ulcerative colitis (UC) is difficult. The clinical
activity index (CAI) is only an indirect assessment tool of bowel inflammation and the endoscopic
activity index (EAI) sometimes cannot reflect the severity of disease to the full extent. Therefore,
there is a need for an objective means to quantify inflammatory activity in mucosal biopsies. In our
study, we wanted to examine the correlation between transcript levels of interleukin 8 (CXCL8),
interferon  γ inducible protein 10 (CXCL10), myeloid-related protein 14 (calgranulin B),
macrophage inflammatory protein 2 α (CXCL2) with CAI and EAI in UC.
Methods: Cytokine and chemokine transcripts were quantified using real-time PCR in 49 mucosal
biopsies from 27 different patients with UC. Cytokine transcript levels were correlated with CAI
and EAI.
Results: There was a statistically significant positive correlation between CXCL8 (r = 0.30; p <
0.05), CXCL10 (r = 0.40; p < 0.02), calgranulin B (r = 0.36; p < 0.03), CXCL2 (r = 0.31; p < 0.05)
and CAI. Concerning EAI significant positive correlations for CXCL8 (r = 0.37; p < 0.02), CXCL10
(r = 0.33; p < 0.04), calgranulin B (r = 0.31; p < 0.05) and CXCL2 (r = 0.44; p < 0.05) were found.
Low clinical and endoscopic activity was accompanied by low cytokine levels whereas high CAI and
EAI were associated with high cytokine levels.
Conclusion: From our data, we conclude that real-time PCR quantification of CXCL8, CXCL10,
calgranulin B and CXCL2 in colonic biopsies is a simple and objective method for grading
inflammation of intestinal mucosa in UC. CXCL8, CXCL10, calgranulin B and CXCL2 might be
used as biomarkers and thus as an objective tool especially in clinical trials to evaluate anti-
inflammatory and immunomodulatory regimens.
Background
Inflammatory bowel disease (IBD) like ulcerative colitis
(UC) and Crohn's disease (CD) are characterized by a
relapsing and remitting clinical course. Disease activity
and severity are variable and include both segmental proc-
esses with slight impairment of state of health and pancol-
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itis with extensive gastrointestinal and systemic
symptoms. Thus, the definition of disease activity in UC is
often difficult. The clinical activity index (CAI) is only an
indirect assessment tool of bowel inflammation and the
endoscopic activity index (EAI) is sometimes unable to
reflect the severity of disease to the full extent.
Cytokine and chemokine mRNA expression profiles in
UC have been characterized in former studies [1-3] and
interleukin 8 (CXCL8), interferon γ inducible protein 10
(CXCL10), myeloid-related protein 14 (calgranulin B)
and macrophage inflammatory protein 2 α (CXCL2) were
identified as important inflammatory mediators. How-
ever, transcript levels of these cytokines and chemokines
in the blood can not reflect the inflammatory activity in
the gut accurately [2,3]. But a correlation between
mucosal mRNA levels of specific cytokines and chemok-
ines measured by real-time PCR and mucosal inflamma-
tion has been shown for CD patients and in patients with
ileopouch anal anastomosis (IPAA) [4,5]. However, so far
no data concerning the correlation between transcript lev-
els of the above mentioned selected pro-inflammatory
cytokines CXCL8, CXCL10, calgranulin B and CXCL2 in
mucosal biopsies and disease activity indices of UC
patients exist. Previous studies either evaluated changes in
other than the above mentioned cytokines/chemokines
like Raddatz et al. [6] who showed a positive correlation
between interleukin 6 (IL-6) mRNA transcript levels and
CAI in patients with pancolitis or used methods like
Northern Blot analysis [7], in situ hybridization [8], ELISA
[7,9-12] or immunohistochemistry [8] which are not con-
sidered reliable for quantification of mucosal cytokine
gene expression. As an adequate treatment of UC requires
an objective assessment of mucosal inflammation, there is
a need for a simple and objective means to quantify
inflammatory activity. The recent development of real
time PCR methodology should allow a routine and relia-
ble quantification of PCR products. Therefore, we meas-
ured the transcript levels of CXCL8, CXCL10, calgranulin
B and CXCL2 in biopsies of UC patients in this study and
correlated them to CAI and EAI.
Thus, the aim of this study was to establish several
biomarkers which can reflect mucosal inflammation in
UC.
Methods
Patients
All biopsies were taken from patients who participated in
one of our clinical studies [13,14]. The biopsies were
taken from the colon section 30–40 cm ab ano to get a
standardization for our study. Our studies were approved
by the institutional Ethics Committee of the University of
Heidelberg. CAI and EAI were assessed according to Rach-
milewitz [15] (tables 1 and 2). Altogether, 49 biopsies
from 27 different patients were examined. In table 3
patients' sociodemographic and clinical data are given.
Nineteen patients were male, eight female. Patients' mean
age was 37 years (range, 18–53 years). Patients' disease
duration averaged out at 9 years (range, 1–23 years). Sev-
enteen of our patients had a pancolitis, nine a left sided
colitis and one patient had only proctitis. In table 4 the
CAI (mean CAI, 6; range, 0–14) and the EAI (mean EAI, 7;
range 2–10) assigned to each biopsy at the time of sam-
pling are shown. Three patients had extraintestinal mani-
festations of UC, namely arthritis. 24 patients received
Table 1: Clinical Activity Index (CAI) according to 
Rachmilewitz.
Number of stools weekly
< 18 0
18–35 1
36–60 2
> 60 3
Blood in stools (based on weekly average)
None 0
Little 1
A lot 2
Investigator's global assessment of symptomatic state
Good 0
Average 1
Poor 2
Very poor 3
Abdominal pain/cramps
None 0
Mild 1
Moderate 2
Severe 3
Temperature due to colitis
< 38°C 0
> 38°C 1
Extraintestinal manifestations
Iritis 3
Erythema nodosum 3
Arthritis 3
Laboratory Findings
Sedimentation rate > 50 mm in 1st hour 1
Sedimentation rate > 100 mm in 1st hour 2
Haemoglobin < 100 g/L 4BMC Gastroenterology 2009, 9:13 http://www.biomedcentral.com/1471-230X/9/13
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drug treatment. A single treatment regimen with pred-
nisolone was given to 7 patients, a single treatment regi-
men with 5-aminosalicylic acid (5-ASA) to 5 patients. 6
patients received prednisolone and 5-ASA, 3 patients
received prednisolone and azathioprine and 3 patients
were treated with prednisolone, 5-ASA and azathioprine.
If one patient was included in our study twice, biopsies
were taken at two different time points at intervals of at
least 3 months.
Real-Time RT-PCR
Biopsies were collected in RNAlater (Ambion, Austin, TX,
USA), and stored at -20°C until analysis. Tissue was dis-
rupted by one run with the RiboLyser (ThermoHYBAID,
Heidelberg) in lysing matrix „D“ tubes (Q-BIOgen, Hei-
delberg) containing 400 μl lysis buffer from the Mag-
naPure mRNA Isolation Kit II (ROCHE Diagnostics,
Mannheim). The RiboLyser tubes were centrifuged at 4°C
for 1 min at 13000 rpm. 300 μl of the lysate was collected
and mixed with 600 μl capture buffer containing oligo-dT.
After centrifugation at 13000 rpm for 5 min, 880 μl of this
mix was transferred into a MagnaPure sample cartridge
and mRNA was isolated with the MagnaPure-LC device
using the mRNA-II standard protocol. The elution volume
was set to 50 μl.
An aliquot of 8.2 μl mRNA was reversely transcribed using
AMV-RT and oligo-(dT) as primer (First Strand cDNA syn-
thesis kit, Roche) according to the manufacturers instruc-
tions in a thermocycler. After termination of the cDNA
synthesis, the reaction mix was diluted to a final volume
of 500 μl and stored at -20°C until PCR analysis.
Primer sets optimized for the LightCycler (RAS, Man-
nheim Germany) were developed and purchased from
SEARCH-LC GmbH, Heidelberg. The PCR was performed
with the LightCycler FastStart DNA Sybr GreenI kit (RAS)
according to the instructions provided in the parameter
specific kits. To control for specificity of the amplification
products, a melting curve analysis was performed. No
amplification of unspecific products was observed. The
copy number was calculated from a standard curve,
obtained by plotting known input concentrations of four
different plasmids at log dilutions to the PCR-cycle
number (CP) at which the detected fluorescence intensity
reaches a fixed value. This approach dramatically reduced
variations due to handling errors over several logarithmic
dilution steps.
To correct for differences in the content of total RNA, the
calculated copy numbers were normalized according to
the average expression of two housekeeping genes, β-
Actin and Cyclophilin B. Values were thus given as input
adjusted copy number per μl of cDNA.
Statistical analysis
Statistical analysis was performed using SAS software
(Release 9.1, SAS Institute, Cary; NC, USA). Results are
described as medians, means and ranges. Correlations
between cytokine/chemokine transcript levels and CAI
and EAI were analyzed using the Pearson correlation coef-
ficient (r) and the corresponding probability value (p).
Multiple linear regression analysis was performed to
examine whether the cytokine/chemokine transcript lev-
els were independently associated with CAI and EAI. To
control a possible bias by more than one biopsy of a per-
son the generalized estimating equation (GEE) method
was used with an independent and an exchangeable work-
Table 2: Endoscopic Activity Index (EAI) according to 
Rachmilewitz.
Granulation scattering reflected light
No 0
Yes 2
Vascular pattern
Normal 0
Faded/disturbed 1
Completely absent 2
Vulnerability of mucosa
None 0
Slightly increased (contact bleeding) 2
Greatly increased (spontaneous bleeding) 4
Mucosal damage (mucus, fibrin, exudate, erosions, ulcer)
None 0
Slight 2
Pronounced 4
Table 3: Patients' characteristics
Number of Patients 27
Sex (m/f) 19/8
Age (years) 37 (18–53)
Disease Duration (years) 9 (1–23)
Disease Localisation: Pancolitis/Left sided colitis/Proctitis 17/9/1
Extraintestinal Manifestations (arthritis) 3
Values are given as absolute numbers and means. The values in brackets give the extreme values.BMC Gastroenterology 2009, 9:13 http://www.biomedcentral.com/1471-230X/9/13
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ing correlation matrix. Two sided probability values were
always computed and an effect was considered statistically
significant at a value of p < 0.05.
Results
Expression of cytokine/chemokine transcripts in mucosal 
biopsies of UC patients
In 49 biopsies from 27 UC patients the expression of
CXCL8, CXCL10, calgranulin B and CXCL2 transcripts
were measured. The median number of transcript copies
in all biopsies was 80 (range, 0–600) for CXCL8, 75
(range, 3–339) for CXCL10, 799 (range, 16–10517) for
calgranulin B and 353 (range, 10–2484) for CXCL2.
Correlation of cytokine/chemokine transcript levels with 
CAI and EAI
To determine the convergence of cytokine/chemokine
transcript levels with the activity of UC, the correlations
between cytokine/chemokine transcript levels and clinical
and endoscopic disease activity were calculated. The cor-
relations between cytokine/chemokine transcript levels
and CAI for all biopsies are shown in figures 1, 2, 3, 4.
There was a statistically significant positive correlation
between CXCL8 (r = 0.30; p < 0.05), CXCL10 (r = 0.40; p
< 0.02), calgranulin B (r = 0.36; p < 0.03) and CXCL2 (r =
0.31; p < 0.05) with CAI. The correlations between
cytokine/chemokine transcript levels and EAI for all biop-
sies are shown in figures 5, 6, 7, 8. Concerning EAI, we
could also find significant positive correlations for CXCL8
(r = 0.37; p < 0.02), CXCL10 (r = 0.33; p < 0.04), calgran-
ulin B (r = 0.31; p < 0.05) and CXCL2 (r = 0.44; p < 0.05).
Positive correlations indicate that clinical and endoscopic
improvement led to a decrease in cytokine levels whereas
Table 4: Biopsies' characteristics
Number of Biopsies 49
Mean CAI 6 (0–14)
Mean EAI 7 (2–10)
Values are given as absolute numbers and means. The values in 
brackets give the extreme values.
Linear regression analysis of CXCL8 transcript levels and  CAI in all biopsies Figure 1
Linear regression analysis of CXCL8 transcript levels 
and CAI in all biopsies. On the x axis, the values of the 
CAI are given. On the y axis, the cytokine transcript levels 
are shown. Each single biopsy is characterized by 1 point 
within the graph. For the graph the related Pearson correla-
tion coefficient (r) and the corresponding probability value 
(p) are given.
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Linear regression analysis of CXCL10 transcript levels and  CAI in all biopsies Figure 2
Linear regression analysis of CXCL10 transcript lev-
els and CAI in all biopsies. On the x axis, the values of the 
CAI are given. On the y axis, the cytokine transcript levels 
are shown. Each single biopsy is characterized by 1 point 
within the graph. For the graph the related Pearson correla-
tion coefficient (r) and the corresponding probability value 
(p) are given.
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Linear regression analysis of calgranulin B transcript levels  and CAI in all biopsies Figure 3
Linear regression analysis of calgranulin B transcript 
levels and CAI in all biopsies. On the x axis, the values of 
the CAI are given. On the y axis, the cytokine transcript lev-
els are shown. Each single biopsy is characterized by 1 point 
within the graph. For the graph the related Pearson correla-
tion coefficient (r) and the corresponding probability value 
(p) are given.
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a deterioration of clinical and endoscopic activity was
accompanied by increased cytokine levels.
Correlation analysis was performed to examine a possible
internal correlation between CXCL8, CXCL10, calgranulin
B and CXCL2. Statistically significant positive correlations
were found between CXCL8 and CXCL2 (r = 0.94; p <
0.0001), between CXCL8 and calgranulin B (r = 0.55; p =
0.0002) and between CXCL2 and calgranulin B (r = 0.46;
p = 0.002). Linear regression analysis revealed then cal-
granulin B (p = 0.0008, p = 0.0007) and CXCL10 (p =
0.0412, p = 0.0873) independently correlated with CAI
and EAI, respectively.
Regarding the variation of CAI and EAI expressed by
CXCL2, CXCL8, CXCL10, and calgranulin B the results of
the linear regression for R-square were 0.360 and 0.216,
respectively.
Discussion
Although there has been progress in understanding the
pathogenesis of IBD in the last decade, the etiology
remains unknown. Therefore, most therapies aim at a
Linear regression analysis of CXCL2 transcript levels and  CAI in all biopsies Figure 4
Linear regression analysis of CXCL2 transcript levels 
and CAI in all biopsies. On the x axis, the values of the 
CAI are given. On the y axis, the cytokine transcript levels 
are shown. Each single biopsy is characterized by 1 point 
within the graph. For the graph the related Pearson correla-
tion coefficient (r) and the corresponding probability value 
(p) are given.
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Linear regression analysis of CXCL8 transcript levels and EAI  in all biopsies Figure 5
Linear regression analysis of CXCL8 transcript levels 
and EAI in all biopsies. On the x axis, the values of the EAI 
are given. On the y axis, the cytokine transcript levels are 
shown. Each single biopsy is characterized by 1 point within 
the graph. For the graph the related Pearson correlation 
coefficient (r) and the corresponding probability value (p) are 
given.
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Linear regression analysis of CXCL10 transcript levels and  EAI in all biopsies Figure 6
Linear regression analysis of CXCL10 transcript lev-
els and EAI in all biopsies. On the x axis, the values of the 
EAI are given. On the y axis, the cytokine transcript levels 
are shown. Each single biopsy is characterized by 1 point 
within the graph. For the graph the related Pearson correla-
tion coefficient (r) and the corresponding probability value 
(p) are given.
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Linear regression analysis of calgranulin B transcript levels  and EAI in all biopsies Figure 7
Linear regression analysis of calgranulin B transcript 
levels and EAI in all biopsies. On the x axis, the values of 
the EAI are given. On the y axis, the cytokine transcript lev-
els are shown. Each single biopsy is characterized by 1 point 
within the graph. For the graph the related Pearson correla-
tion coefficient (r) and the corresponding probability value 
(p) are given.
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symptomatic treatment of inflammation. However, objec-
tive assessment of mucosal inflammation and disease
activity is often difficult. Neither CAI nor EAI, as estab-
lished scores, can characterize mucosal inflammation and
disease activity to the full extent. The CAI is influenced by
patients' perception and may thus reflect clinical symp-
toms due to other factors than mucosal inflammation and
the severity of endoscopic lesions often do not correlate
with clinical severity.
The aim of our study was to find a simple and objective
means to quantify inflammatory activity in colonic
mucosa of UC patients. Therefore, we tried to establish
several biomarkers, which can reflect mucosal inflamma-
tion in UC.
Thus, we measured the transcript levels of CXCL8,
CXCL10, calgranulin B and CXCL2 in biopsies of UC
patients and correlated them to CAI and EAI.
The new and substantial finding of our study is the signif-
icant positive correlation between transcript levels of
CXCL8, CXCL10, calgranulin B and CXCL2 and both CAI
and EAI.
Our results agree with the literature. For CXCL8, which is
the major attractant and activator of neutrophils
[9,10,16], a high expression of mRNA in UC patients with
high disease activity has been described [8]. Another
group [17], who performed immunohistochemistry and
image analysis found enhanced CXCL10 expression in
UC. CXCL10 selectively attracts activated T lymphocytes.
Calgranulin B is selectively secreted by human monocytes
and granulocytes. Using ELISA technique an increased
serum level was detected in UC patients with active dis-
ease [18]. The same group [19] could also show a greater
calgranulin B production in CD in ulcerative and fissural
lesions than in uninflamed areas. Concerning CXCL2,
which is extremely chemotactic for neutrophils [20], an
upregulated expression of mRNA and protein in inflamed
gut, predominantly in UC has been shown [1].
These data from the literature strengthen our findings that
CXCL8, CXCL10, calgranulin B and CXCL2 are objective
indicators of disease activity and severity in UC.
Conclusion
Therefore, we conclude that measuring transcript levels of
CXCL8, CXCL10, calgranulin B and CXCL2 by RT-PCR is
a fast, simple and objective method to quantify mucosal
inflammation in UC. This approach can give important
information in addition to CAI and EAI and thus provide
an objective marker of intestinal inflammation. Moreo-
ver, using this technique to monitor therapeutic effects of
e. g. novel drugs can offer potential improvement in clin-
ical research.
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